Somatic and Germline Mutation Analysis in Inherited and Acquired Aplastic Anemia
Indian Journal of Hematology and Blood Transfusion · 2026-11 · 42 (6) · 2291-2303
DOI: 10.1007/s12288-026-02580-8 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Indian Journal of Hematology and Blood Transfusion, online erschienen am 27.09.2026. Verfasst von Ekta Jajodia und 1 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Genetics, Unipath Specialty Laboratory, Unigenome, Ahmedabad, India. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Aplastic anemia (AA) is a life-threatening bone marrow failure syndrome characterized by pancytopenia and a hypocellular marrow. Most cases are idiopathic, making AA a diagnosis of exclusion after ruling out other causes of marrow hypocellularity such as hypoplastic myelodysplastic syndrome (MDS) and inherited bone marrow failure syndromes (IBMFS). The distinction is clinically critical, as treatment strategies, prognosis, and family counseling differ significantly across these entities. The diagnostic challenge between AA and hypoplastic MDS is particularly evident in children, in whom hypocellularity is common in MDS, unlike the typically hypercellular marrow seen in adults. While clonal cytogenetic abnormalities can support MDS diagnosis, many childhood MDS cases and even some adults lack chromosomal abnormalities. Moreover, somatic mutations in genes such as DNMT3A, ASXL1, and BCOR/BCORL1 occur in both AA and MDS, further blurring the diagnostic boundary. Next-generation sequencing (NGS) and cytogenetics are therefore essential not only for differential diagnosis but also for risk stratification, as clones such as DNMT3A and ASXL1 predict poor response to immunosuppressive therapy and higher risk of neoplastic evolution. Clonal evolution is a hallmark of AA, occurring in both neoplastic and non-neoplastic forms. Approximately 15% of patients progress to MDS or acute myeloid leukemia (AML) within a decade, while non-neoplastic evolution involves the emergence of paroxysmal nocturnal hemoglobinuria (PNH) clones in 40-50% of cases. PNH clone detection, particularly when granulocyte clones exceed 1%, is highly predictive of immune-mediated AA and correlates with favorable response to immunosuppressive therapy. Equally important is the recognition of IBMFS, which account for up to 25% of pediatric and 5-15% of young adult AA cases. These syndromes may present solely with AA, lacking classical syndromic features, underscoring the need for a high index of suspicion and appropriate genetic testing. Accurate diagnosis informs management, guides transplantation, enables genetic counseling, and improves long-term outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Molecular Genetics, Unipath Specialty Laboratory, Unigenome, Ahmedabad, India.
- Hematology and Bone Marrow Transplant, Marengo CIMS Hospital, Ahmedabad, India.
ORCID-Profile: Ekta Jajodia
Zitieren
APA
Jajodia, E., & Jitani, A. (2026). Somatic and Germline Mutation Analysis in Inherited and Acquired Aplastic Anemia. Indian Journal of Hematology and Blood Transfusion, 42(6), 2291-2303. https://doi.org/10.1007/s12288-026-02580-8
Vancouver
Jajodia E, Jitani A. Somatic and Germline Mutation Analysis in Inherited and Acquired Aplastic Anemia. Indian Journal of Hematology and Blood Transfusion. 2026;42(6):2291-2303. doi:10.1007/s12288-026-02580-8
BibTeX
@article{Jajodia2026,
author = {Jajodia, Ekta and Jitani, Ankit},
title = {Somatic and Germline Mutation Analysis in Inherited and Acquired Aplastic Anemia},
journal = {Indian Journal of Hematology and Blood Transfusion},
year = {2026},
volume = {42},
number = {6},
pages = {2291--2303},
doi = {10.1007/s12288-026-02580-8}
}
EUVIMED